Ideally, combining PTEN-targeted therapy to classical chemotherapy should be a promising strategy, leading to (a) normalization of the tumor vasculature, (b) sensitization of cancer cells to further chemo- and radiotherapy, and (c) avoidance of resistance to such treatments. This evidence concerns the gene PTEN and cancer.